Zacks Research Has Bullish Forecast for CRSP FY2024 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Analysts at Zacks Research boosted their FY2024 earnings estimates for CRISPR Therapeutics in a research report issued to clients and investors on Tuesday, November 26th. Zacks Research analyst R. Department now expects that the company will earn ($5.20) per share for the year, up from their previous forecast of ($6.13). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.20) per share. Zacks Research also issued estimates for CRISPR Therapeutics' Q4 2024 earnings at ($1.27) EPS, Q1 2025 earnings at ($1.51) EPS, Q2 2025 earnings at ($1.47) EPS, Q3 2025 earnings at ($1.37) EPS, Q4 2025 earnings at ($1.26) EPS, FY2025 earnings at ($5.61) EPS, Q1 2026 earnings at ($1.28) EPS, Q2 2026 earnings at ($0.91) EPS, Q3 2026 earnings at ($0.25) EPS and FY2026 earnings at ($2.24) EPS.

Several other brokerages also recently weighed in on CRSP. Stifel Nicolaus decreased their target price on CRISPR Therapeutics from $60.00 to $59.00 and set a "hold" rating for the company in a research note on Tuesday, August 6th. Truist Financial cut their target price on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a "buy" rating for the company in a research note on Monday, August 12th. Chardan Capital reduced their target price on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a "buy" rating for the company in a research note on Tuesday, August 6th. Needham & Company LLC reaffirmed a "buy" rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Finally, Barclays lowered their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating on the stock in a research report on Wednesday, November 6th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $74.94.

CRISPR Therapeutics Trading Up 3.1 %

CRSP traded up $1.53 during trading on Thursday, hitting $50.84. The stock had a trading volume of 1,012,731 shares, compared to its average volume of 1,487,962. CRISPR Therapeutics has a 12 month low of $43.42 and a 12 month high of $91.10. The company has a 50 day simple moving average of $48.05 and a 200-day simple moving average of $51.69. The firm has a market cap of $4.34 billion, a PE ratio of -17.96 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The firm had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. During the same period in the previous year, the company earned ($1.41) EPS.

Hedge Funds Weigh In On CRISPR Therapeutics

Several large investors have recently made changes to their positions in CRSP. State Street Corp raised its holdings in CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company's stock worth $140,611,000 after purchasing an additional 599,304 shares during the last quarter. FMR LLC raised its stake in shares of CRISPR Therapeutics by 1.0% during the third quarter. FMR LLC now owns 2,376,166 shares of the company's stock worth $111,632,000 after buying an additional 23,075 shares during the last quarter. Vanguard Group Inc. lifted its holdings in CRISPR Therapeutics by 2.9% in the first quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company's stock valued at $111,564,000 after buying an additional 46,148 shares during the period. Geode Capital Management LLC grew its holdings in CRISPR Therapeutics by 3.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company's stock worth $47,383,000 after acquiring an additional 35,196 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in shares of CRISPR Therapeutics by 2.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 950,149 shares of the company's stock valued at $51,326,000 after acquiring an additional 19,094 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

Insider Buying and Selling

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the company's stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares of the company's stock, valued at approximately $2,896,989.16. This represents a 1.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the sale, the chief executive officer now directly owns 226,540 shares of the company's stock, valued at $10,484,271.20. This trade represents a 1.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 35,382 shares of company stock worth $1,917,679 in the last 90 days. Corporate insiders own 4.10% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.